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Serous borderline tumors are rare neoplasms. Herein we report our conservative approach, whose rationale is neoplasm
low-malignant potential. Tumor was removed under general anesthesia, and frozen section ruled out a germinal malig-
nancy or a stromal tumor such as rhabdomyosarcoma. Ultrasound evaluation was initially performed every 3 months
during the first 2 years, every 6 months during the next 3 years, and annually thereafter. After 8 years, the patient has
not experienced any relapse, either clinical or ultrasonographical. In our opinion, conservative approach, whose final
decision relies on intraoperative frozen section, represents the best option and does not jeopardize long-term oncologi-
cal outcome. UROLOGY 89: 123–125, 2016. © 2016 Elsevier Inc.
Serous borderline tumor (SBT) of the testis repre-sents a rare neoplasm; histologically, it resembles itsovarian counterpart.1,2 Its oncological behavior is not
well defined, given the paucity of literature on this topic.
Case reports and small caseloads show that radical orchi-
ectomy is the treatment most often used.1-3 We describe
herein our conservative approach and pathological char-
acteristics of an SBT that occurred in a 14-year-old patient
8 years ago.
CASE PRESENTATION
A 14-year-old male presented to the emergency depart-
ment complaining of testicular pain over the past 2 days.
A careful objective examination revealed a 7-8 mm mass
indissociable from the right didymus. After ultrasonographical
evaluation (Fig. 1) and tumor marker panel serology, which
was negative, an excisional biopsy was planned. On July 2007,
the testicle was exposed, under general anesthesia, and the
neoplasia, adherent to the tunica albuginea, was removed.
Macroscopical tumor aspect was polipoid; mass consis-
tency was mucinous. The specimen was sent for a frozen
section. This ruled out a germinal malignancy or a stromal
tumor such as rabdomyosarcoma. Moreover, histological
evaluation showed a tumor with papillae covered by neo-
plastic epithelium with no malignant features, thus
orchiectomy was not performed. The tumor was localized
at tunica albuginea level, hence, after removal, this was
sewn, given the small mass diameter.
We evaluated the effectiveness and oncological safety
of our conservative approach through a strict follow-up over
the past 8 years. Ultrasound evaluation was initially per-
formed every 3 months during the first 2 years, every 6
months during the next 3 years, and annually thereafter.
RESULTS
Pathological examination revealed a serous borderline pap-
illary tumor (Fig. 2).
Immunohistochemical evaluation confirmed the preop-
erative diagnosis and demonstrated positivity for AE1/AE3,
CK7, CA125, ER, PR, WT1, BER EP4, EMA, and PAX8
markers. Immunohistochemical examination was nega-
tive for calretinin, trombomodulin, caldesmon, CEA, D2
40, CK5/6, CDX2, CK20, CD117, CD30, alpha fetopro-
tein, beta hcg, desmin, and B72.3.
After 8 years, the patient has not experienced any relapse,
either clinical or ultrasonographical.
COMMENT
Because literature did not produce cases of relapses or me-
tastasis for SBT,2,4,5 we had adopted a conservative ap-
proach, of which final decision would have been based on
extemporaneous pathological examination.
SBTs are rare entities. Only four cases have been re-
ported in literature as occurring in pediatric patients.3,6-8
Paratesticular tumors can have malignant characteristics,
especially in case of serous carcinoma or sarcoma.5,9
As paratesticular tumor, rhabdomyosarcoma is more fre-
quent compared to SBT.9 Rhabdomyosarcoma’s standard
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multimodal treatment relies on the local control of the
primary site with radical orchiectomy, chemotherapy, and
radiotherapy according to stage, histology, and age of the
patient.10 If the frozen section had shown rhabdomyosar-
coma, hemiscrotectomy along with high ligation of the sper-
matic cord would have been performed. Because surgery
alone produced approximately a 50% 2-year relapse-free
survival,11 systemic chemotherapy alone or combined
chemo- and radiotherapy would have been adopted to maxi-
mize tumor control, thus resulting in increased morbidity.
Our case concerns a borderline tumor, whose malig-
nant potential seems to be inconsistent.1-5 Its treatment is
classically reported to be total orchiectomy.1-3 In the four
previously reported pediatric cases, radical orchiectomy has
been the treatment of choice in three3,6,7 whereas one only
describes tumor resection.8
Eight years follow-up of the present case confirms and
supports the conservative approach given the low malig-
nant SBT potential.
SBTs have been reported to occur in patients from 14
to 68 years of age, usually manifesting themselves as scrotal
enlargement.12 Their origin is still under debate. One theory
affirms that ovarian-type epithelial tumors of the testis origi-
nate from Müllerian ducts remnants in paratesticular con-
nective tissue, epididymis, and spermatic cord, whereas
another states that SBT is the result of Müllerian meta-
plasia of the tunica vaginalis mesothelium. This latter theory
is supported by frequent findings of metaplastic serous
Müllerian epithelium in these tumors.13 Hormonal influ-
ences concerning the risk of SBT developing in the
paratestis are unknown; it is not clear if long-term topical
testosterone may have a role.5
One of the key steps in the diagnosis of ovarian-type epi-
thelial tumors is distinguishing them from clinically ag-
gressive neoplasms such as tunica vaginalis mesothelioma,
and carcinoma of the rete testis. Beyond histological fea-
tures of mesothelioma, immunohistochemical evaluation
of mesothelial markers such as D2-40, thrombomodulin,
and calretinin can be helpful for assessing tumor nature.14
Our pathological results are in keeping with those find-
ings. Quite often, serous tumors show an opposite immu-
nohistochemical pattern for those antigens and express
ovarian epithelial tumor markers such as epithelial mem-
brane antigen, CA-125, cytokeratin 7, CD15 (Leu-1), and
Ber-EP4.14 Because PAX8 expression in ovarian-type epi-
thelial tumors is usually expressed, it represents a valu-
able tool when differentiating this neoplasm from malignant
mesothelioma, that, on the contrary, rarely expresses it.15
CONCLUSION
Our experience in conservative approach to SBT has dem-
onstrated safety over a long-term follow-up period. Because
literature does not produce cases of metastasis or relapse
for this kind of tumor, our conservative approach, in our
opinion, represents the best option and does not jeopar-
dize long-term oncological outcome.
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